TP53 and lung neuroendocrine neoplasm: Poor survival and increased aggressiveness in lung NET patients have been attributed to mutations in the TP53 gene [17], which might be mirrored by the differing tumorigenicity of the cell lines in SCID mice and the concordant bi-allelic deletion of TP53 in the P-STS cell line.